Skip to main content

Table 2 Number (percentage) of RA patients with damage to any or to multiple large joints as well as with uni- or bilateral erosive (Larsen score ≥2) large joints after 11 years of follow-up, by initial randomization group

From: Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial

  Original randomization group
  FIN-RACo (n = 52) SINGLE (n = 54)
Damage to any large joint 7 (13%)   15 (28%)  
Damage to multiple (two to three) large joints 5 (10%)   10 (19%)  
Radiographed joint Unilateral damage Bilateral damage Unilateral damage Bilateral damage
Shoulder 0 2 (4%) 4 (7%) 7 (13%)
Elbow 1 (2%) 0 1 (2%) 1 (2%)
Hip 3 (6%) 2 (4%) 4 (7%) 1 (2%)
Knee 3 (6%) 1 (2%) 2 (4%) 0
  1. FIN-RACo, study group treated for the first 2 years with a combination of three disease-modifying antirheumatic drugs, initially methotrexate, sulfasalazine, and hydroxychloroquine, with prednisolone; RA, rheumatoid arthritis; SINGLE, study group treated for the first 2 years with one disease-modifying antirheumatic drug, initially sulfasalazine, with or without prednisolone.